FOLFIRINOX: From the ACCORD study to 2014

Journal of the Pancreas

Volumn 15, Issue 2, 2014, Pages 103-105

  Oikonomopoulos, Georgios M ^a   Syrigos, Konstantinos N ^b   Skoura, Evangelia ^c   Saif, Muhammad Wasif ^d  

^a Second Oncology Department 'St Savvas' Anticancer Hospital   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

Drug Therapy; Irinotecan; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANEMIA; BORDERLINE RESECTABLE PANCREATIC CANCER; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER; PANCREAS CANCER; PANCREAS METASTASIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); SENSORY NEUROPATHY; SURVIVAL RATE; SYMPOSIUM; THROMBOCYTOPENIA; VOMITING;

EID: 84897889265     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: 10.6092/1590-8577%2F2278     Document Type: Conference Paper

References (8)

1. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
2. Sophie Gourgou-Bourgade, Caroline Bascoul-Mollevi, Françoise Desseigne, et al.: Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial. J Clin Oncol 31:23-29, 2012
3. Brian A. Boone et al. Outcomes with FOLFIRINOX for locally advanced pancreatic cancer. J Clin oncol 30:2012 (suppl 34;abstr 256)
4. Peter J. Hosein, Jessica Macintyre, Carolina Kawamura, et al.: A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012, 12:199
5. Parvin F Peddi, Sam Lubner, Robert McWilliams, et al.: Multi- Institutional Experience with FOLFIRINOX in Pancreatic Adenocarcinoma. J Pancreas (Online) 2012 Sep 10; 13(5):497-501.
6. Edward Samuel James, Xiaopan Yao, Xiangyu Cong, et al.: Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). J Clin Oncol 32, 2014 (suppl 3; abstr 256)
7. Marlo A. Blazer, Christina Sing-Ying Wu, Richard M. Goldberg,et al.: Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC). J Clin Oncol 32, 2014 (suppl 3; abstr 275)
8. Jean Philippe Metges, Jean François Ramée, Jean-Yves Douillard, et al.: Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer. J Clin Oncol 32, 2014 (suppl 3; abstr 305)